![Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea](https://mma.prnewswire.com/media/1803054/Axsome_R_Morpheus_Logo.jpg?p=facebook)
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
![Solriamfetol Efficacy and Safety for Treatment of Excessive Daytime Sleepiness in People With Narcolepsy or OSA Is Consistent Across Trials - Practical Neurology Solriamfetol Efficacy and Safety for Treatment of Excessive Daytime Sleepiness in People With Narcolepsy or OSA Is Consistent Across Trials - Practical Neurology](https://core4.bmctoday.net/storage/images/1560520372-SolriamfetolTable.jpg)
Solriamfetol Efficacy and Safety for Treatment of Excessive Daytime Sleepiness in People With Narcolepsy or OSA Is Consistent Across Trials - Practical Neurology
![Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression - ScienceDirect Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S002239562200471X-ga1.jpg)
Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression - ScienceDirect
![These highlights do not include all the information needed to use SUNOSI safely and effectively. See full prescribing information for SUNOSI. SUNOSI® (solriamfetol) tablets, for oral use, CIVInitial U.S. Approval: 2019 These highlights do not include all the information needed to use SUNOSI safely and effectively. See full prescribing information for SUNOSI. SUNOSI® (solriamfetol) tablets, for oral use, CIVInitial U.S. Approval: 2019](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-05.jpg&id=638702)
These highlights do not include all the information needed to use SUNOSI safely and effectively. See full prescribing information for SUNOSI. SUNOSI® (solriamfetol) tablets, for oral use, CIVInitial U.S. Approval: 2019
![These highlights do not include all the information needed to use SUNOSI safely and effectively. See full prescribing information for SUNOSI. SUNOSI® (solriamfetol) tablets, for oral use, CIVInitial U.S. Approval: 2019 These highlights do not include all the information needed to use SUNOSI safely and effectively. See full prescribing information for SUNOSI. SUNOSI® (solriamfetol) tablets, for oral use, CIVInitial U.S. Approval: 2019](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-06.jpg&id=638702)
These highlights do not include all the information needed to use SUNOSI safely and effectively. See full prescribing information for SUNOSI. SUNOSI® (solriamfetol) tablets, for oral use, CIVInitial U.S. Approval: 2019
![Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice | Neurotherapeutics Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice | Neurotherapeutics](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs13311-022-01328-2/MediaObjects/13311_2022_1328_Fig5_HTML.png)
Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice | Neurotherapeutics
![Solriamfetol for the Management of Excessive Daytime Sleepiness - Megan C Cuomo, Amy H Sheehan, Joe K Jordan, 2022 Solriamfetol for the Management of Excessive Daytime Sleepiness - Megan C Cuomo, Amy H Sheehan, Joe K Jordan, 2022](https://journals.sagepub.com/cms/10.1177/08971900211009080/asset/images/large/10.1177_08971900211009080-fig1.jpeg)